Novartis acquires Excellergy, a startup focused on developing allergy treatments, in hopes of finding a successor to their current drug Xolair. The deal, worth up to $280 million, includes an upfront payment of $10 million and potential milestone payments.

Access impact
The acquisition of Excellergy could potentially have a significant impact on the pricing and reimbursement of Novartis’ future allergy drugs. Xolair, currently priced at $1,500 per dose, has faced criticism for its high cost and limited accessibility. If Excellergy is successful in developing a more affordable and effective alternative, it could lead to increased competition in the market and potentially drive down prices for patients.

Top-3 domain lens
Clinical Effectiveness
According to the article, Excellergy’s lead drug candidate has shown promising results in early clinical trials, with a potential to treat both food and environmental allergies. This could potentially lead to improved clinical effectiveness compared to Xolair, which only treats environmental allergies.

Cost-Effectiveness
The high cost of Xolair has been a major barrier for patients seeking treatment for their allergies. If Excellergy is able to develop a more cost-effective alternative, it could have a significant impact on the market and potentially improve patient access to these much-needed treatments.

Evidence Quality and Robustness
Novartis’ decision to acquire Excellergy is based on the promising early data of their lead drug candidate. As more data becomes available through later clinical trials, the evidence quality and robustness of the drug’s effectiveness will be further assessed, potentially impacting its pricing and reimbursement.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug

CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list

Source
source: https://www.biopharmadive.com/news/novartis-excellergy-allergy-drugs-deal-xolair/815956/